Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31610737 | 0.63 | CYP1A1 (0.45) | CHRNB2CHRNA4CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL13361961 | 0.63 | CYP17A1 (0.34) | CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL3326422 | 0.62 | PSEN1 (0.38) | KCNH2 | |
| SCHEMBL3324518 | 0.61 | PTGS2 (0.38) | CYP11B1CYP11B2CYP1A2PTGS2 | |
| SCHEMBL27314054 | 0.60 | MAP3K12 (0.42) | — | |
| SCHEMBL23641248 | 0.60 | PIK3CA (0.38) | — | |
| SCHEMBL30031982 | 0.60 | PIK3CA (0.38) | — | |
| SCHEMBL7914351 | 0.58 | PTGS2 (0.37) | CYP11B1CYP11B2KCNH2CYP1A2PTGS2 | |
| SCHEMBL5702666 | 0.58 | CYP1A1 (0.74) | CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL21044243 | 0.56 | PRMT5 (0.49) | BACE1CYP11B1CYP11B2KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | BACE1 1251/4885CHRNB2 1425/4885CHRNA4 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.